IP Library › Granted Patent US 12,427,151
Granted Patent B2
US 12,427,151 · App. 17/578,130 · Granted Sep 30, 2025

Compositions and method of treating cancer

Inventors: Richard L. Gallo (San Diego, CA); Teruaki Nakatsuji (San Diego, CA)
Assignee: The Regents of the University of California
A61K31/52A61K9/0014A61K9/06A61K35/741A61P31/00A61P35/00A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,427,151
App. No.
17/578,130
Granted
Sep 30, 2025
Kind
B2
Abstract

The disclosure describes methods and compositions for treating or preventing skin damage due to UV radiation. For example, the method includes contacting the skin with an effective amount of a composition containing the compound

Claims (25)

1. A method for treating or preventing skin damage due to UV radiation comprising contacting the skin with an effective amount of a composition comprising a compound of Formula I(a):

or a pharmaceutically acceptable salt thereof, wherein,

N 1 -N 5 are nitrogen atoms;

X 1 -X 2 are carbon atoms;

the R groups attached by a dashed line are present, or are not present if the R group is connected to an atom that is bound to another atom by a double covalent bond;

the bond indicated by both a straight line and a dashed line indicate that the bond may be a single covalent bond or a double covalent bond;

the fused heterocyclic ring system comprises three double bonds with N 2 or N 3 forming a double bond and with X 1 , and with N 4 or N 5 forming a double bond with X 2 ;

R 1 is a hydroxyl; and

R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently a H, D, optionally substituted (C 1 -C 3 )-alkyl.

2. The method of claim 1 , wherein the method treats or prevents skin damage leading to a cancer selected from the group consisting of melanoma, squamous cell carcinoma, actinic keratosis, keratoacanthoma, and basal cell carcinoma.

3. The method of claim 1 , wherein the contacting is through topical administration.

4. The method of claim 1 , wherein the composition further comprises one or more sunscreen agents.

5. The method of claim 4 , wherein one or more sunscreen agents comprises aminobenzoic acid, avobenzone, cinoxate, dioxybenzone, ecamsule, ensulizole, homosalate, meradimate, octocrylene, octinoxate, octisalate, oxybenzone, padimate O, sulisobenzone, titanium dioxide, trolamine salicylate, and zinc oxide.

6. The method of claim 1 , wherein the composition is formulated for topical administration.

7. The method of claim 1 , wherein the composition is formulated as a spray, lotion, shake lotion, cream, ointment, gel, foam, powder, solid, paste or tincture.

8. The method of claim 1 , wherein the composition comprises a commensal probiotic bacteria that produces the compound of Formula I(a)

a compound of Formula I(b)

or a compound of Formula II

9. The method of claim 8 , wherein the commensal probiotic bacteria expresses one or more of the sequences set forth in SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, and/or 55.

10. The method of claim 8 , wherein the commensal probiotic bacteria comprises S. epidermidis strain MO34 and/or MO38.

11. The method of claim 1 , wherein the composition improves healing and reduces morbidity associated with skin damage.

12. The method of claim 1 , wherein the method treats or prevents a neoplasm caused by UV-induced skin damage.

13. The method of claim 1 , wherein the composition further comprises one or more topical antibiotics.

14. The method of claim 13 , wherein the one or more topical antibiotics comprises sulfacetamide sodium, bacitracin, polymyxin b, erythromycin, silver sulfadiazine, neomycin, retapamulin, and mupirocin.

15. The method of claim 1 , wherein the composition comprises one or more gelling agents selected from the group comprising crosslinked acrylic acid polymers, hydrophilic polymers, cellulosic polymers, gums, or any combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2025
From: GALLO, RICHARD L.; NAKATSUJI, TERUAKI
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 071353/0119 →
Continuity (4)
Division 16497430
Provisional Application 62638058 · Mar 2, 2018
Provisional Application 62477370 · Mar 27, 2017
Related Publication 20220241288A1 · Aug 4, 2022
References Cited (25)
US 11260058B2 · Gallo · 2022 [cited by examiner]
US 20050043328A1 · Dolezal et al. · 2005 [cited by applicant]
US 20130331384A1 · Gallo et al. · 2013 [cited by applicant]
US 20130338173A1 · Olhava et al. · 2013 [cited by applicant]
CN 1465582A · 2004 [cited by applicant]
EP 1724258A1 · 2006 [cited by applicant]
WO 9839334A1 · 1998 [cited by applicant]
WO 2007135380A2 · 2007 [cited by applicant]
Abdul-Masih et al., “Biochemical Studies on the Mutagen, 6-N-Hydroxylaminopurine”, The Journal of Biological Chemistry, Feb. 15, 1986, vol. 261, No. 5, pp. 2020-2026. [cited by applicant]
Umeda, Takashi, Notification of Completion of Re-Examination, Japan Patent Office, Application No. 2019-552970, Appeal or Trial No. 2023-008456, Jul. 4, 2023. [cited by applicant]
Bakkestuen et al., “Synthesis and antimycobacterial activity of agelasine E and analogs”, Org. Biomol. Chem., Jan. 1, 2005, vol. 3, No. 6, pp. 1025-1033. [cited by applicant]
Davenport, K.W., et al., “Complete Genome Assembly of [cited by applicant]
Giner-Sorolla et al., “Synthesis and Properties of Some 6-Substituted Purines”, Proc. Soc. Expl. Biol. and Med., 1958, vol. 80, No. 15, pp. 3932-3937. [cited by applicant]
Krajewski et al., “Antibacterial and antivirulence effect of 6-N-hydroxylaminopurine in Listeria monocytogenes”, Nucleic Acids Research, Jan. 6, 2017, vol. 45, No. 4, pp. 1914-1924. [cited by applicant]
Lai et al., “Commensal skin bacteria as the probiotic of the cutaneous immune response”, Expert Review of Dermatology, vol. 5, No. 3, Jun. 1, 2010, pp. 251-253. [cited by applicant]
Nakatsuji et al., “A commensal strain of [cited by applicant]
Renard, Dephine, Extended European Search Report, Patent Application No. 18774237.4, European Patent Office, Dec. 2, 2020. [cited by applicant]
Sartorelli et al., “Some inhibitory properties of 6-N-Hydroxylaminopurine: An analog of adenine and hypoxanthine”, Biochemical Pharmacology, Mar. 1, 1964, vol. 13, No. 3, pp. 507-515. [cited by applicant]
Shealy et al., Journal of Pharmaceutical Scences, 62(8):1252-7, 1973. [cited by applicant]
Wang, Xin, International Preliminary Report on Patentability and Written Opinion, PCT/US2018/024511, The International Bureau of WIPO, Oct. 10, 2019. [cited by applicant]
Young, Lee W., International Search Report and Written Opinion, PCT/US2018/024511, United States Patent and Trademark Office, Aug. 24, 2018. [cited by applicant]
Nakatsuji, T., “Firmocidin, a small molecule produced by S. epidermidis, provides antineoplastic and anti-biotic function from the commensal skin microbiome”, Journal of Investigative Dermatology, May 2014, vol. 134, pp… [cited by applicant]
Renard, Delphine, Office Action, Application No. 18774237.4, European Patent Office, Dec. 7, 2023. [cited by applicant]
Giner-Sorolla et al., “The Synthesis and Biological Properties of Hydroxylaminopurines and Related Derivatives”, Journal of Medicinal Chemistry, May 1, 1968, 11(3), pp. 521-523. [cited by applicant]
Jean, Laura, Office Action, Canadian Intellectual Property Office, Application No. 3,057,978, May 17, 2024. [cited by applicant]